OMDA:NASDAQOmada Health, Inc. Analysis

Omada Health posted a remarkable 42% year‑over‑year revenue growth in Q1 2026, helped by a guidance raise and an EPS beat of roughly 38%, which has sparked strong investor enthusiasm as reflected by the Extreme Greed sentiment (fear‑greed index 87.3). The stock trades at $17.42, comfortably above its 20‑day SMA ($17.28) and 50‑day SMA ($15.39), yet it sits near the calculated support level of $15.97 and below the resistance at $18.71, indicating limited upside in the near term. Technical momentum is mixed: RSI is neutral at 54.8, while the MACD histogram is negative and the signal line is deemed bearish, suggesting a potential short‑term pullback. Volatility is high (≈59% 30‑day) and beta exceeds 1.2, underscoring a price that swings more than the market, though the company carries no debt and holds over $211 M in cash. Fundamental valuation shows the DCF fair value at $13.65, implying the market price is currently overvalued, while the forward PE of 36.5× sits well above the industry average of 24.8×. Despite a negative operating margin and modest profitability, the strong cash flow generation and expanding virtual‑care franchise provide a solid growth narrative.